Lauren S L Price
5PUBLICATIONS
60CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (5)
Sort by Publication Date:
|Aug 27, 2025
FDA Approval Summary: Datopotamab Deruxtecan-dlnk for Treatment of Patients with Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer.Melanie Royce, Mirat Shah, Lijun Zhang
|Aug 22, 2025
US Food and Drug Administration Approval Summary: Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Locally Advanced or Metastatic Breast Cancer.Suparna Wedam, Preeti Narayan, Haley Gittleman
|Oct 16, 2024
FDA Approval Summary: Teclistamab-A Bispecific CD3 T-Cell Engager for Patients with Relapsed or Refractory Multiple Myeloma.Andrea C Baines, Bindu Kanapuru, Jay Zhao
|Jun 02, 2023
FDA Approval Summary: Selpercatinib for the Treatment of Advanced RET Fusion-Positive Solid Tumors.Elizabeth S Duke, Diana Bradford, Michelle Marcovitz
|Aug 25, 2020
A reanalysis of nanoparticle tumor delivery using classical pharmacokinetic metrics.Lauren S L Price, Stephan T Stern, Allison M Deal
Pageof 1
Frequent Collaborators
3 joint publications
Richard Pazdur
2 joint publications
Shenghui Tang
2 joint publications
William Pierce
2 joint publications
Vishal Bhatnagar
2 joint publications
Laleh Amiri-Kordestani
2 joint publications
Sarah E Dorff
1 joint publications
Alexander V Kabanov
1 joint publications
Paul G Kluetz
1 joint publications
Diana Bradford
1 joint publications
Michelle Marcovitz
